Provectus Biopharmaceuticals Enters Material Definitive Agreement
Ticker: PVCT · Form: 8-K · Filed: Dec 26, 2024 · CIK: 315545
| Field | Detail |
|---|---|
| Company | Provectus Biopharmaceuticals, Inc. (PVCT) |
| Form Type | 8-K |
| Filed Date | Dec 26, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: PVCT
TL;DR
Provectus Bio (PVCT) signed a big deal on 12/20. Details to come.
AI Summary
On December 20, 2024, Provectus Biopharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal office in Knoxville, TN, filed this 8-K report on December 26, 2024, detailing the agreement.
Why It Matters
This filing indicates a significant new contract or partnership for Provectus Biopharmaceuticals, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not yet detailed in this initial filing.
Key Players & Entities
- PROVECTUS BIOPHARMACEUTICALS, INC. (company) — Registrant
- December 20, 2024 (date) — Date of earliest event reported
- December 26, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Knoxville, TN (location) — Business address
FAQ
What is the nature of the material definitive agreement entered into by Provectus Biopharmaceuticals?
The filing states that an "Entry into a Material Definitive Agreement" is an item of information, but the specific details of the agreement are not provided in this initial 8-K report.
When was the material definitive agreement entered into?
The earliest event reported, which includes the entry into the material definitive agreement, occurred on December 20, 2024.
What is Provectus Biopharmaceuticals' state of incorporation?
Provectus Biopharmaceuticals, Inc. is incorporated in Delaware.
Where is Provectus Biopharmaceuticals' principal place of business?
The company's business address is listed as 800 S. Gay Street, Suite 1610, Knoxville, TN 37929.
What is the SEC file number for this filing?
The SEC file number for this 8-K filing is 001-36457.
Filing Stats: 553 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-12-26 09:30:09
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex10-1.htm (EX-10.1) — 23KB
- 0001493152-24-052029.txt ( ) — 230KB
- pvct-20241220.xsd (EX-101.SCH) — 3KB
- pvct-20241220_lab.xml (EX-101.LAB) — 33KB
- pvct-20241220_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 800 S. Gay Street , Suite 1610 , Knoxville , Tennessee 37929 (Address of Principal Executive Offices) (Zip Code) (866) 594-5999 (Registrant's Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2 below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: None Title of each class Trading Symbol(s) Name of each exchange on which registered Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 1.01. Entry into a Material Definitive Agreement. Pursuant to Provectus Biopharmaceuticals, Inc.'s (the "Company's") exclusive license agreement with the University of Miami (the "University") for the development and commercialization of the University's intellectual property related to photodynamic antimicrobial therapy in ophthalmology entered into on March 21, 2024 (the "License Agreement") and the approval of the Board of Directors of the Company on December 5, 2024 to transfer certain assets to VisiRose, Inc. ("VisiRose"), a majority-owned subsidiary of the Company focused on the development and commercialization of the Company's pharmaceutical-grade active pharmaceutical ingredient rose bengal sodium for the treatments of ophthalmology diseases and disorders, the Company and VisiRose entered into an agreement on December 20, 2024 where by the Company assigned the License Agreement to VisiRose, which the University approved (the "Assignment and Assumption Agreement"). The full text of the Assignment and Assumption Agreement is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated by reference into this Item 1.01. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Assignment and Assumption Agreement, dated December 20, 2024, by and between the Company and VisiRose and approved by the University 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 26, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. By: /s/ Heather Raines Heather Raines Chief Financial Officer (Principal Financial Officer)